Insights On Pharmaceutical Production

41. Virus Reduction Of An Affinity Capture Step: Viral Clearance For Protein A 5/17/2019

    Learn more about how HiScale 10/40, packed with MabSelect PrismA, is a reliable choice for the capture step in a virus clearance study.

42. Standing Out In The Crowded Biopharma CDMO Market 3/14/2019

    When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection they are able to communicate what is unique about their offering to the right audience at the right time. 

43. Lyophilization Of Highly Potent Drugs: Facility and Equipment Design Elements 5/24/2019

    Because scale-up and technology transfer of the lyophilization process is challenging, it is important to develop a comprehensive understanding of critical lyophilization characteristics early on.

44. Is Your CMO Ready For Serialization And Aggregation? 3/20/2019

    While some are waiting for mandates for traceability, serialization, and aggregation, others are recognizing the inevitability of these strategies. Does your CMO have a dedicated traceability operation in place?

45. Adenovirus Production In Single-Use Xcellerex™ XDR-10 Bioreactor System 9/10/2018

    This application note describes the production of adenovirus in HEK293 cells cultured in HyClone™ CDM4HEK293 culture medium.

46. Meeting The Changing Demands For Sterile-Fill Finish Operations 10/16/2018

    Meeting the growing demand for fill-finish services requires specialized expertise, appropriate equipment and innovations in both emerging technology and business models.

47. Optimization Of Midstream Cell Lysis And Virus Filtration Steps In An Adenovirus Purification Process 9/10/2018

    Here we describe screening of detergents for release of adenovirus from HEK293 host cells to replace the traditionally used detergent Triton™.

48. Transform With An Equipment Partner: Preparing For Serialization 10/16/2018

    Factors to consider as your organization works to conform to the serialization guidelines.

49. The Future Of Highly Potent API Manufacturing - Lonza Perspective 5/7/2020

    Highly potent active pharmaceutical ingredients (HPAPIs) represent an increasing fraction of new compounds in pharmaceutical pipelines today. Flexible and phase-appropriate infrastructure is needed to bring the next innovative medicines based on these challenging compounds from concept to commercialization. Thispresentation describes Lonza's HPAPI "manufacturing 4.0" investments and the company's innovative capabilities.

50. Custom Amplification Products 5/22/2020

    This video details Promega’s capabilities for custom amplification products. See how they can modify amplification products to suit their customer’s specific needs.